Combination treatment with sulforaphane and gefitinib dose-dependently inhibits the expression of SHH, SMO, and GLI1 and suppresses the proliferation of gefitinib-resistant lung cancer cells through the SHH signaling pathway [30]. Here, SHH is linked to lung cancer.